MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RxSight, Inc. - Common Stock (NQ:RXST)

6.570 +0.310 (+4.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,153,131
Open 6.260
Bid (Size) 5.990 (400)
Ask (Size) 6.600 (5,000)
Prev. Close 6.260
Today's Range 6.245 - 6.585
52wk Range 4.480 - 13.22
Shares Outstanding 33,981,877
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
RxSight Q2 Earnings Call Highlights ↗
RxSight (NASDAQ:RXST) reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026... 
Via MarketBeat
Topics Earnings
RxSight (NASDAQ:RXST) Slips After Q2 Revenue Matches, Loss Narrows ↗
Via Chartmill

Performance

YTD
-36.7%
-36.7%
1 Month
+32.7%
+32.7%
3 Month
+15.3%
+15.3%
6 Month
-20.5%
-20.5%
1 Year
-1.2%
-1.2%

More News

Read More
News headline image
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
From RxSight, Inc.
Via GlobeNewswire
News headline image
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
From RxSight, Inc.
Via GlobeNewswire
News headline image
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
From RxSight, Inc.
Via GlobeNewswire
RxSight (NASDAQ:RXST) Q1 2026 Results: Revenue Beats but Loss Widens Amid Cautious Market Reaction ↗
Via Chartmill
RXSIGHT INC (NASDAQ:RXST) Reports Q4 Beat but Cautious 2026 Outlook Weighs on Shares ↗
Via Chartmill
News headline image
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook ↗
Via MarketBeat
News headline image
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
From RxSight, Inc.
Via GlobeNewswire
News headline image
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
From RxSight, Inc.
Via GlobeNewswire
News headline image
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
From RxSight, Inc.
Via GlobeNewswire
News headline image
RxSight (RXST) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
From RxSight, Inc.
Via GlobeNewswire
News headline image
RxSight, Inc. to Present at the Bank of America Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
News headline image
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
From RxSight, Inc.
Via GlobeNewswire
News headline image
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
News headline image
RxSight (RXST) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
From RxSight, Inc.
Via GlobeNewswire
News headline image
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
From RxSight, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST
From Pomerantz LLP
Via GlobeNewswire
News headline image
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
From RxSight, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is RxSight, Inc. - Common Stock publicly traded?
Yes, RxSight, Inc. - Common Stock is publicly traded.
What exchange does RxSight, Inc. - Common Stock trade on?
RxSight, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for RxSight, Inc. - Common Stock?
The ticker symbol for RxSight, Inc. - Common Stock is RXST on the Nasdaq Stock Market
What is the current price of RxSight, Inc. - Common Stock?
The current price of RxSight, Inc. - Common Stock is 6.570
When was RxSight, Inc. - Common Stock last traded?
The last trade of RxSight, Inc. - Common Stock was at 08/10/26 04:00 PM ET
What is the market capitalization of RxSight, Inc. - Common Stock?
The market capitalization of RxSight, Inc. - Common Stock is 223.26M
How many shares of RxSight, Inc. - Common Stock are outstanding?
RxSight, Inc. - Common Stock has 223M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story